Unknown

Dataset Information

0

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.


ABSTRACT: AIM:To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100?units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy. MATERIALS AND METHODS:In this 26-week, phase IIIb, open-label, parallel-group, treat-to-target trial, conducted at 74 sites in 11 countries, insulin-naïve people aged ?18?years with glycated haemoglobin (HbA1c) 53-97 mmol/mol (7.0-11.0%), body mass index 20-40?kg/m2 and inadequately controlled type 2 diabetes (T2D) on SGLT2 inhibitor ± oral antidiabetic drugs were randomized 1:1 to once-daily IDegLira or IGlar U100, both as add-on to existing therapy. The primary endpoint was change in HbA1c from baseline to week 26. RESULTS:A total of 210 participants were randomized to each treatment arm. Mean HbA1c reductions were 21 mmol/mol (1.9%-points) with IDegLira and 18 mmol/mol (1.7%-points) with IGlar U100; confirming non-inferiority (P?

SUBMITTER: Philis-Tsimikas A 

PROVIDER: S-EPMC6593861 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.

Philis-Tsimikas Athena A   Billings Liana K LK   Busch Robert R   Portillo Cristobal Morales CM   Sahay Rakesh R   Halladin Natalie N   Eggert Sarah S   Begtrup Kamilla K   Harris Stewart S  

Diabetes, obesity & metabolism 20190404 6


<h4>Aim</h4>To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add-on to sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy.<h4>Materials and methods</h4>In this 26-week, phase IIIb, open-label, parallel-group, treat-to-target trial, conducted at 74 sites in 11 countries, insulin-naïve people aged ≥18 years with glycated haemoglobin (HbA1c) 53-97 mmol/mol (7.0-11.0%), body mass index 20-40 kg/m<sup>2</sup>  ...[more]

Similar Datasets

| S-EPMC8665002 | biostudies-literature
| S-EPMC8286333 | biostudies-literature
| S-EPMC5984929 | biostudies-literature
| S-EPMC6167291 | biostudies-literature
| S-EPMC6891960 | biostudies-literature
| S-EPMC6618254 | biostudies-literature
| S-EPMC5817473 | biostudies-literature
| S-EPMC5817477 | biostudies-literature
| S-EPMC6336128 | biostudies-literature
| S-EPMC9017614 | biostudies-literature